{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T04:55:02Z","timestamp":1772340902872,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41434-025-00551-8","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T01:22:03Z","timestamp":1752196923000},"page":"487-496","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transabdominal ultrasound guided AAV9-GFP delivery in fetal pigs: a translational and minimally invasive model for in utero fetal gene therapy"],"prefix":"10.1038","volume":"32","author":[{"given":"Alessia","family":"Di Donfrancesco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Adelizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Giri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Duchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Boito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Barandalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Santanatoglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Cappellozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Perota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4616-5623","authenticated-orcid":false,"given":"Ivano","family":"Di Meo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Tiranti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Bottani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9028-9597","authenticated-orcid":false,"given":"Nicola","family":"Persico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-9370","authenticated-orcid":false,"given":"Dario","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"551_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrd3835-c1","volume":"12","author":"D Melchiorri","year":"2013","unstructured":"Melchiorri D, Pani L, Gasparini P, Cossu G, Ancans J, Borg JJ, et al. Regulatory evaluation of Glybera in Europe \u2014 two committees, one mission. Nat Rev Drug Discov. 2013;12:719.","journal-title":"Nat Rev Drug Discov"},{"key":"551_CR2","doi-asserted-by":"crossref","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849\u201360.","DOI":"10.1016\/S0140-6736(17)31868-8"},{"key":"551_CR3","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322.","journal-title":"N Engl J Med"},{"key":"551_CR4","doi-asserted-by":"publisher","first-page":"e679","DOI":"10.1097\/HS9.0000000000000679","volume":"6","author":"RMT Ten Ham","year":"2022","unstructured":"Ten Ham RMT, Walker SM, Soares MO, Frederix GWJ, Leebeek FWG, Fischer K, et al. Modeling benefits, costs, and affordability of a novel gene therapy in Hemophilia A. HemaSphere. 2022;6:e679.","journal-title":"HemaSphere"},{"key":"551_CR5","doi-asserted-by":"crossref","unstructured":"Hemgenix - A gene therapy for hemophilia B. Med Lett Drugs Ther. 2023;65:9\u201310.","DOI":"10.58347\/tml.2023.1668a"},{"key":"551_CR6","doi-asserted-by":"crossref","unstructured":"Delandistrogene moxeparvovec (Elevidys) for Duchenne muscular dystrophy. Med Lett Drugs Ther. 2023;65:159\u201360.","DOI":"10.58347\/tml.2023.1686d"},{"key":"551_CR7","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/pd.6228","volume":"42","author":"ME Schwab","year":"2022","unstructured":"Schwab ME, Shao S, Zhang L, Lianoglou B, Belter L, Jarecki J, et al. Investigating attitudes toward prenatal diagnosis and fetal therapy for spinal muscular atrophy. Prenat Diagn. 2022;42:1409\u201319.","journal-title":"Prenat Diagn"},{"key":"551_CR8","first-page":"442","volume":"11","author":"DR Deyle","year":"2010","unstructured":"Deyle DR, Russell DW. Adeno-associated virus vector integration. Curr Opin Mol Therapeutics. 2010;11:442.","journal-title":"Curr Opin Mol Therapeutics"},{"key":"551_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"551_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1021\/acssynbio.2c00589","volume":"12","author":"LT Collins","year":"2023","unstructured":"Collins LT, Ponnazhagan S, Curiel DT. Synthetic biology design as a paradigm shift toward manufacturing affordable adeno-associated virus gene therapies. ACS Synth Biol. 2023;12:17\u201326.","journal-title":"ACS Synth Biol"},{"key":"551_CR11","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","volume":"11","author":"G Ronzitti","year":"2020","unstructured":"Ronzitti G, Gross DA, Mingozzi F. Human immune responses to adeno-associated virus (AAV) vectors. Front Immunol. 2020;11:670.","journal-title":"Front Immunol"},{"key":"551_CR12","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3390\/pharmaceutics14061287","volume":"14","author":"A Di Donfrancesco","year":"2022","unstructured":"Di Donfrancesco A, Massaro G, Di Meo I, Tiranti V, Bottani E, Brunetti D. Gene therapy for mitochondrial diseases: current status and future perspective. Pharmaceutics. 2022;14:1287.","journal-title":"Pharmaceutics"},{"key":"551_CR13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/jimd.12659","volume":"47","author":"SN Waddington","year":"2024","unstructured":"Waddington SN, Peranteau WH, Rahim AA, Boyle AK, Kurian MA, Gissen P, et al. Fetal gene therapy. J Inher Metab Disea. 2024;47:192\u2013210.","journal-title":"J Inher Metab Disea"},{"key":"551_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.stem.2018.08.010","volume":"23","author":"TC MacKenzie","year":"2018","unstructured":"MacKenzie TC. Future AAVenues for in utero gene therapy. Cell Stem Cell. 2018;23:320\u20131.","journal-title":"Cell Stem Cell"},{"key":"551_CR15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molmed.2021.05.007","volume":"27","author":"SK Bose","year":"2021","unstructured":"Bose SK, Menon P, Peranteau WH. In utero gene therapy: progress and challenges. Trends Mol Med. 2021;27:728\u201330.","journal-title":"Trends Mol Med"},{"key":"551_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1089\/hum.2010.007","volume":"22","author":"AL David","year":"2011","unstructured":"David AL, McIntosh J, Peebles DM, Cook T, Waddington S, Weisz B, et al. Recombinant adeno-associated virus-mediated in utero gene transfer gives therapeutic transgene expression in the sheep. Hum Gene Ther. 2011;22:419\u201326.","journal-title":"Hum Gene Ther"},{"key":"551_CR17","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1038\/mt.2011.107","volume":"19","author":"CNZ Mattar","year":"2011","unstructured":"Mattar CNZ, Nathwani AC, Waddington SN, Dighe N, Kaeppel C, Nowrouzi A, et al. Stable human FIX expression after 0.9G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques. Mol Ther. 2011;19:1950\u201360.","journal-title":"Mol Ther"},{"key":"551_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/gt.2011.216","volume":"20","author":"CN Mattar","year":"2013","unstructured":"Mattar CN, Waddington SN, Biswas A, Johana N, Ng XW, Fisk AS, et al. Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems. Gene Ther. 2013;20:69\u201383.","journal-title":"Gene Ther"},{"key":"551_CR19","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/j.ymthe.2017.04.003","volume":"25","author":"CNZ Mattar","year":"2017","unstructured":"Mattar CNZ, Gil-Farina I, Rosales C, Johana N, Tan YYW, McIntosh J, et al. In utero transfer of adeno-associated viral vectors produces long-term factor IX levels in a cynomolgus macaque model. Mol Ther. 2017;25:1843\u201353.","journal-title":"Mol Ther"},{"key":"551_CR20","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1016\/j.ymthe.2024.05.005","volume":"32","author":"K Pekrun","year":"2024","unstructured":"Pekrun K, Stephens CJ, Gonzalez-Sandoval A, Goswami A, Zhang F, Tarantal AF, et al. Correlation of antigen expression with epigenetic modifications after rAAV delivery of a human factor IX variant in mice and rhesus macaques. Mol Ther. 2024;32:2064\u201379.","journal-title":"Mol Ther"},{"key":"551_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd5758","volume":"13","author":"JK Lunney","year":"2021","unstructured":"Lunney JK, Van Goor A, Walker KE, Hailstock T, Franklin J, Dai C. Importance of the pig as a human biomedical model. Sci Transl Med. 2021;13:eabd5758.","journal-title":"Sci Transl Med"},{"key":"551_CR22","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.bbadis.2018.03.021","volume":"1864","author":"C Quadalti","year":"2018","unstructured":"Quadalti C, Brunetti D, Lagutina I, Duchi R, Perota A, Lazzari G, et al. SURF1 knockout cloned pigs: early onset of a severe lethal phenotype. Biochim Biophys Acta Mol Basis Dis. 2018;1864:2131\u201342.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"551_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3389\/fimmu.2019.00727","volume":"10","author":"SN Langel","year":"2019","unstructured":"Langel SN, Paim FC, Alhamo MA, Buckley A, Van Geelen A, Lager KM, et al. Stage of gestation at porcine epidemic diarrhea virus infection of pregnant swine impacts maternal immunity and lactogenic immune protection of neonatal suckling piglets. Front Immunol. 2019;10:727.","journal-title":"Front Immunol"},{"key":"551_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","volume":"10","author":"J Hordeaux","year":"2018","unstructured":"Hordeaux J, Hinderer C, Goode T, Katz N, Buza EL, Bell P, et al. Toxicology study of intra-cisterna magna adeno-associated virus 9 expressing human alpha-L-iduronidase in rhesus macaques. Mol Ther Methods Clin Dev. 2018;10:79\u201388.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"551_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer C, Katz N, Buza EL, Dyer C, Goode T, Bell P, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther. 2018;29:285\u201398.","journal-title":"Hum Gene Ther"},{"key":"551_CR26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143780","volume":"131","author":"M Muhuri","year":"2021","unstructured":"Muhuri M, Maeda Y, Ma H, Ram S, Fitzgerald KA, Tai PWL, et al. Overcoming innate immune barriers that impede AAV gene therapy vectors. J Clin Investig. 2021;131:e143780.","journal-title":"J Clin Investig"},{"key":"551_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/brainsci10020119","volume":"10","author":"BA Perez","year":"2020","unstructured":"Perez BA, Shutterly A, Chan YK, Byrne BJ, Corti M. Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases. Brain Sci. 2020;10:119.","journal-title":"Brain Sci"},{"key":"551_CR28","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41434-023-00401-5","volume":"30","author":"DH Chand","year":"2023","unstructured":"Chand DH, Sun R, Diab KA, Kenny D, Tukov FF. Review of cardiac safety in onasemnogene abeparvovec gene replacement therapy: translation from preclinical to clinical findings. Gene Ther. 2023;30:685\u201397.","journal-title":"Gene Ther"},{"key":"551_CR29","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1053\/j.gastro.2011.04.002","volume":"141","author":"E Breous","year":"2011","unstructured":"Breous E, Somanathan S, Bell P, Wilson JM. Inflammation causes loss of adeno-associated virus-mediated transgene expression in mouse liver. Gastroenterology. 2011;141:348\u2013357.e3.","journal-title":"Gastroenterology"},{"key":"551_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41423-020-00580-w","volume":"18","author":"Y He","year":"2021","unstructured":"He Y, Hwang S, Ahmed YA, Feng D, Li N, Ribeiro M, et al. Immunopathobiology and therapeutic targets related to cytokines in liver diseases. Cell Mol Immunol. 2021;18:18\u201337.","journal-title":"Cell Mol Immunol"},{"key":"551_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131617","volume":"398","author":"E Silver","year":"2024","unstructured":"Silver E, Argiro A, Hong K, Adler E. Gene therapy vector-related myocarditis. Int J Cardiol. 2024;398:131617.","journal-title":"Int J Cardiol"},{"key":"551_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"JH Wang","year":"2024","unstructured":"Wang JH, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Sig Transduct Target Ther. 2024;9:78.","journal-title":"Sig Transduct Target Ther"},{"key":"551_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02013-x","volume":"16","author":"T Vaisitti","year":"2021","unstructured":"Vaisitti T, Peritore D, Magistroni P, Ricci A, Lombardini L, Gringeri E, et al. The frequency of rare and monogenic diseases in pediatric organ transplant recipients in Italy. Orphanet J Rare Dis. 2021;16:374.","journal-title":"Orphanet J Rare Dis"},{"key":"551_CR34","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJMra1201534","volume":"369","author":"CJL Murray","year":"2013","unstructured":"Murray CJL, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369:448\u201357.","journal-title":"N Engl J Med"},{"key":"551_CR35","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/bdr2.1589","volume":"111","author":"CT Mai","year":"2019","unstructured":"Mai CT, Isenburg JL, Canfield MA, Meyer RE, Correa A, Alverson CJ, et al. National population\u2010based estimates for major birth defects, 2010\u20132014. Birth Defects Res. 2019;111:1420\u201335.","journal-title":"Birth Defects Res"},{"key":"551_CR36","unstructured":"WHO Birth defects. 2022. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/birth-defects."},{"key":"551_CR37","doi-asserted-by":"crossref","unstructured":"Peddi NC, Marasandra Ramesh H, Gude SS, Gude SS, Vuppalapati S. Intrauterine fetal gene therapy: is that the future and is that future now? Cureus. 2022;14(2):e22521.","DOI":"10.7759\/cureus.22521"},{"key":"551_CR38","doi-asserted-by":"crossref","unstructured":"Mattar CNZ, Chan JKY, Choolani M. Gene modification therapies for hereditary diseases in the fetus. Prenatal Diagn. 2023;43:674\u201386.","DOI":"10.1002\/pd.6347"},{"key":"551_CR39","doi-asserted-by":"crossref","first-page":"s4","DOI":"10.1038\/scientificamerican0419-4","volume":"320","author":"S Deweerdt","year":"2019","unstructured":"Deweerdt S. Some genetic diseases cause damage even before a child is born. The answer to these devastating conditions could lie in gene therapy delivered while the baby is still in the womb. Sci Am. 2019;320:s4\u20136.","journal-title":"Sci Am"},{"key":"551_CR40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41434-021-00305-2","volume":"29","author":"KA Rich","year":"2022","unstructured":"Rich KA, Wier CG, Russo J, Kong L, Heilman PL, Reynolds A, et al. Premature delivery in the domestic sow in response to in utero delivery of AAV9 to fetal piglets. Gene Ther. 2022;29:513\u20139.","journal-title":"Gene Ther"},{"key":"551_CR41","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41434-023-00395-0","volume":"30","author":"A Dave","year":"2023","unstructured":"Dave A, Berkowitz CL, Luks VL, White BM, Palanki R, Carpenter MD, et al. Comment on: premature delivery in the domestic sow in response to in utero delivery of AAV9 to fetal piglets. Gene Ther. 2023;30:232\u20135.","journal-title":"Gene Ther"},{"key":"551_CR42","doi-asserted-by":"crossref","unstructured":"Rahim AA, Wong AMS, Hoefer K, Buckley SMK, Mattar CN, Cheng SH, et al. Intravenous administration of AAV2\/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system. FASEB J. 2011;25:3505\u201318.","DOI":"10.1096\/fj.11-182311"},{"key":"551_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05862-9","volume":"22","author":"A Adelizzi","year":"2024","unstructured":"Adelizzi A, Giri A, Di Donfrancesco A, Boito S, Prigione A, Bottani E, et al.\u00a0 Fetal and obstetrics manifestations of mitochondrial diseases. J Transl Med. 2024;22:853.","journal-title":"J Transl Med"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00551-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00551-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00551-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:31:41Z","timestamp":1760369501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00551-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1038\/s41434-025-00551-8","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures involving the use of animals in this study were approved by the Local Ethics Committee of Avantea, carried out under the Italian Law (D. Lgs 26\/2014) and EU directive 2010\/63\/EU regulating animal experimentation, and approved by relevant national authorities (Ministry of Health project n\u00b0 367\/2022-PR). All the animal studies were done according to the ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to publish this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}